Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Market Outlook

Thelansis’s “Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Overview

Ovarian cancer is a type of malignancy that occurs in women. The majority of ovarian cancers, up to 90%, originate from the epithelial cells of the ovary. These cancers can be further classified into subtypes based on their histological and immunohistochemical characteristics, with the most common subtypes being high-grade serous (70%), low-grade serous, high-grade endometrioid, low-grade endometrioid, clear cell, and mucinous carcinomas. Low-grade serous carcinoma of the ovary or peritoneum (LGSC) is a rare subtype, accounting for between 5 and 8% of all ovarian carcinomas. LGSC can develop from a precursor lesion known as a serous borderline ovarian tumor (SBOT) or a de novo malignancy in the ovary or peritoneum. Patients with LGSC may present with non-specific symptoms such as abdominal discomfort, bloating, dyspnea, dyspepsia, and changes in bowel movement patterns. Alternatively, it may arise from the malignant transformation of a borderline ovarian tumor. LGSOC is characterized by being WT1 positive (95%), p53 wild-type (90%), ER-positive (57%), and PR positive (78%). Additionally, LGSOC typically presents with activating mutations in the RAS-RAF-MEK-ERK pathway. The neoplasm usually appears as a solid cystic mass involving the ovarian surface and parenchyma, with sizes ranging from 0.2 cm to over 20 cm. Bilaterality is present in approximately 50% of cases. The contents of the tumor are typically serosanguineous or watery and straw-coloured and less frequently mucinous. Patients with low-grade serous carcinoma tend to be younger than those with high-grade tumors, with a mean age of 45–57 years and 55–65 years, respectively.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in the lipoprotein lipase gene, leading to hypertriglyceridemia and chylomicron accumulation in plasma. High triglycerides can result in complications like acute pancreatitis. FCS is also known as Lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, and Endogenous hypertriglyceridemia. Diagnosis is based on fasting triglyceride levels exceeding 750 mg/dL and can be confirmed through genetic testing. Symptoms can emerge in infancy, childhood, or adolescence, with some patients remaining asymptomatic until adulthood. Common signs include Lipemia Retinalis (milky appearance in retinal veins), eruptive xanthomas (skin bumps with fatty deposits), abdominal pain, milky blood, and pancreatitis. Repeated pancreatitis is a severe complication that can lead to long-term pancreatic dysfunction and potential fatality if left untreated. FCS patients face a higher risk of pancreatiti...
Read more